Pascoe Richard W
Known title: Executive ChairmanCIK: 0001343266
Pascoe Richard W's purchase track record
How the stock did after each of Pascoe Richard W's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 30, 2021
Stock higher 6 months later
25%
3 months: 75%
Median 6-month return
-10.9%
3 months: +13.2%
Beat the S&P 500
25%
median -17.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/9/2023 | ZVRA | $42K | +30.1% | +24.0% | +13.6% |
| 1/13/2023 | ZVRA | $52K | +13.8% | -14.0% | +12.7% |
| 5/18/2022 | ZVRA | $25K | +12.6% | -7.8% | +0.9% |
| 11/30/2021 | ZVRA | $12K | -27.3% | -40.9% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Open Market | 10,000 | $42K | 3/9/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 9,500 | $52K | 1/13/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 300 | $1K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 100 | $490 | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 400 | $2K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 400 | $2K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,767 | $9K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,700 | $8K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 333 | $2K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,500 | $12K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.